Evidence map›Paper›PMID 29143652›Full record

ArticleParasites & vectors2017

Genetic profiles of ten Dirofilaria immitis isolates susceptible or resistant to macrocyclic lactone heartworm preventives.

Catherine Bourguinat, Kathy Keller, Jianguo Xia, Pierre Lepage, Tom L McTier, Debra J Woods, Roger K Prichard

Abstract read
In one paragraph

Article in Parasites & vectors, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Pathogens (Basel, Switzerland) · 2022
    Article
  7. Concern forPathogens (Basel, Switzerland) · 2021
    Review
  8. Article
  9. Whole-genome reference ofCurrent research in parasitology & vector-borne diseases · 2021
    Article
  10. Article
  11. Challenges and opportunities for the adoption of molecular diagnostics for anthelmintic resistance.International journal for parasitology. Drugs and drug resistance · 2020
    Article
  12. Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics.International journal for parasitology. Drugs and drug resistance · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Clinical validation of molecular markers of macrocyclic lactone resistance in Dirofilaria immitis.International journal for parasitology. Drugs and drug resistance · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine BourguinatInstitute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte Anne de Bellevue, QC, H9X3V9, Canada.
Kathy KellerInstitute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte Anne de Bellevue, QC, H9X3V9, Canada.
Jianguo XiaInstitute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte Anne de Bellevue, QC, H9X3V9, Canada.
Pierre LepageMcGill University and Génome Québec Innovation Centre, Montréal, QC, Canada.
Tom L McTierZoetis, Veterinary Medicine Research and Development, Kalamazoo, MI, USA.
Debra J WoodsZoetis, Veterinary Medicine Research and Development, Kalamazoo, MI, USA.
Roger K PrichardInstitute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte Anne de Bellevue, QC, H9X3V9, Canada. roger.prichard@mcgill.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFor dogs and cats, chemoprophylaxis with macrocyclic lactone (ML) preventives for heartworm disease is widely used in the United States and other countries. Since 2005, cases of loss of efficacy (LOE) of heartworm preventives have been reported in the U.S. More recently, ML-resistant D. immitis isolates were confirmed. Previous work identified 42 genetic markers that could predict ML response in individual samples. For field surveillance, it would be more appropriate to work on microfilarial pools from individual dogs with a smaller subset of genetic markers.

methodsMiSeq technology was used to identify allele frequencies with the 42 genetic markers previously reported. Microfilaria from ten well-characterized new isolates called ZoeKY, ZoeMI, ZoeGCFL, ZoeAL, ZoeMP3, ZoeMO, ZoeAMAL, ZoeLA, ZoeJYD-34, and Metairie were extracted from fresh blood from dogs. DNA were extracted and sequenced with MiSeq technology. Allele frequencies were calculated and compared with the previously reported susceptible, LOE, and resistant D. immitis populations.

resultsThe allele frequencies identified in the current resistant and susceptible isolates were in accordance with the allele frequencies previously reported in related phenotypes. The ZoeMO population, a subset of the ZoeJYD-34 population, showed a genetic profile that was consistent with some reversion towards susceptibility compared with the parental ZoeJYD-34 population. The Random Forest algorithm was used to create a predictive model using different SNPs. The model with a combination of three SNPs (NODE_42411_RC, NODE_21554_RC, and NODE_45689) appears to be suitable for future monitoring.

conclusionsMiSeq technology provided a suitable methodology to work with the microfilarial samples. The list of SNPs that showed good predictability for ML resistance was narrowed. Additional phenotypically well characterized D. immitis isolates are required to finalize the best set of SNPs to be used for large scale ML resistance screening.

Indexed as

AnimalsChemopreventionDirofilaria immitisDirofilariasisDog DiseasesDogsFemaleFilaricidesGenetic MarkersLactonesMaleParasitic Sensitivity TestsPolymorphism, Single NucleotideFilaricidesGenetic MarkersLactonesDirofilaria immitisGenetic markersHeartwormMacrocyclic lactone resistancePredictive model

Identifiers

PMID29143652
PMCPMC5688420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.